CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
Learn about the emerging role of CDH6-targeting antibody–drug conjugates for ovarian cancer with Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard MD, PhD, discussing the latest results and implications of studies evaluating raludotatug deruxtecan and other agents.
Decera Clinical Education Oncology Podcast · Kathleen N. Moore MD MS FASCO, Isabelle Ray-Coquard MD PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:
- Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
- Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
- How R-DXd may be incorporated into the treatment paradigm
- Other investigational CDH6-targeting ADCs: CUSP06, SIM0505
Presenters:
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer Center at the University of Oklahoma
Professor
Department of OB/Gyn
ASCO BOD
Oklahoma City, Oklahoma
Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Reshape Lab Inserm u1290
Université Claude Bernard Lyon Est
Lyon, France
Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Link to full program:
https://bit.ly/43PXoeP
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.